Patents by Inventor Rainer Constien

Rainer Constien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipids and compositions for intracellular delivery of biologically active compounds
    Patent number: 9636302
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: May 2, 2017
    Assignee: AXOLABS GMBH
    Inventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS
    Publication number: 20160324781
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 10, 2016
    Inventors: Rainer CONSTIEN, Anke GEICK, Philipp HADWIGER, Torsten HANEKE, Ludger ICKENSTEIN, Carla Alexandra HERNANDEZ PRATA, Andrea SCHUSTER, Timo WEIDE
  • Lipids and compositions for intracellular delivery of biologically active compounds
    Patent number: 9433681
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: September 6, 2016
    Assignee: AXOLABS GMBH
    Inventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • Lipids and compositions for intracellular delivery of biologically active compounds
    Patent number: 9278130
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: March 8, 2016
    Assignee: AXOLABS GMBH
    Inventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • Lipids and compositions for intracellular delivery of biologically active compounds
    Patent number: 9149531
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: October 6, 2015
    Assignee: AXOLABS GMBH
    Inventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS
    Publication number: 20150050295
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Application
    Filed: February 12, 2014
    Publication date: February 19, 2015
    Applicant: AXOLABS GMBH
    Inventors: RAINER CONSTIEN, ANKE GEICK, PHILIPP HADWIGER, TORSTEN HANEKE, LUDGER MARKUS ICKENSTEIN, CARLA ALEXANDRA HERNANDEZ PRATA, ANDREA SCHUSTER, TIMO WEIDE
  • NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS
    Publication number: 20140170175
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 19, 2014
    Applicant: AXOLABS GMBH
    Inventors: RAINER CONSTIEN, ANKE GEICK, PHILIPP HADWIGER, TORSTEN HANEKE, LUDGER MARKUS ICKENSTEIN, CARLA ALEXANDRA HERNANDEZ PRATA, ANDREA SCHUSTER, TIMO WEIDE
  • NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS
    Publication number: 20140162934
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 12, 2014
    Applicant: AXOLABS GMBH
    Inventors: Rainer CONSTIEN, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS
    Publication number: 20140162962
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 12, 2014
    Applicant: AXOLABS GMBH
    Inventors: Rainer CONSTIEN, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • Lipids and compositions for intracellular delivery of biologically active compounds
    Patent number: 8691750
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: April 8, 2014
    Assignee: Axolabs GmbH
    Inventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds
    Publication number: 20120295832
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Application
    Filed: May 8, 2012
    Publication date: November 22, 2012
    Applicant: ARROWHEAD RESEARCH CORPORATION
    Inventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • RNAi Modulation of AHA and Therapeutic Uses Thereof
    Publication number: 20120142757
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Application
    Filed: January 4, 2012
    Publication date: June 7, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • RNAi Modulation Of TGF-BETA And Therapeutic Uses Thereof
    Publication number: 20120108646
    Abstract: The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.
    Type: Application
    Filed: October 29, 2010
    Publication date: May 3, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Hans-Peter Vornlocher, Pamela Tan, Rainer Constien
  • RNAi modulation of Aha and therapeutic uses thereof
    Patent number: 8114984
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: February 14, 2012
    Assignees: Alnylam Pharmaceuticals, Inc., The Scripps Research Institute
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF GLUCOCORTICOID RECEPTOR (GCR) GENES
    Publication number: 20110020300
    Abstract: This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a GCR gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a GCR gene using said pharmaceutical composition; and methods for inhibiting the expression of GCR in a cell.
    Type: Application
    Filed: May 14, 2010
    Publication date: January 27, 2011
    Applicant: GENENTECH, INC.
    Inventors: JACQUES BAILLY, AGNÈS BÉNARDEAU, BIRGIT BRAMLAGE, RAINER CONSTIEN, ANDREA FORST, MARKUS HOSSBACH, BRIGITTE SCHOTT
  • RNAi Modulation of AHA and Therapeutic Uses Thereof
    Publication number: 20110003882
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Application
    Filed: September 7, 2010
    Publication date: January 6, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • RNAi modulation of TGF-beta and therapeutic uses thereof
    Patent number: 7846908
    Abstract: The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: December 7, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, Pamela Tan, Rainer Constien
  • RNAi modulation of Aha and therapeutic uses thereof
    Patent number: 7812150
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: October 12, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PTP1B GENES
    Publication number: 20100197773
    Abstract: This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a PTP1B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a PTP1B gene using said pharmaceutical composition; and methods for inhibiting the expression of PTP1B in a cell.
    Type: Application
    Filed: January 29, 2010
    Publication date: August 5, 2010
    Inventors: Birgit Bramlage, Rainer Constien, Andrea Forst, Markus Hossbach, John Reidhaar-Olson, Cristina Martha Rondinone, Hans-Peter Vornlocher
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENES
    Publication number: 20100124547
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Factor VII gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a Factor VII gene using said pharmaceutical composition; and methods for inhibiting the expression of Factor VII in a cell.
    Type: Application
    Filed: November 12, 2009
    Publication date: May 20, 2010
    Inventors: Birgit Bramlage, Rainer Constien, Jacques Himber, Markus Hossbach, Pamela Tan, Hans-Peter Vornlocher